Advanced search
Publication Cover
Journal of Medical Economics Volume 12, 2009 - Issue 4
Submit an article Journal homepage
436
Views
23
CrossRef citations to date
0
Altmetric
Original Article

Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System

M. Fuller Pharmacy Services, Louis Stokes Cleveland VAMC, Brecksville, OH, USACorrespondence[email protected]
,
K. Shermock Center for Pharmaceutical Outcomes and Policy, The Johns Hopkins Hospital, Baltimore, MD, USA
,
P. Russo Health Services Research and Management Consulting, Washington, DC, USA
,
M. Secic Secic Statistical Consulting, Inc., Chardon, OH, USA
,
R. Dirani Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
,
S. Vallow Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
&
S. Flanders Formerly Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
 show all
Pages 317-324 | Published online: 12 Oct 2009

References

  • McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(Suppl 5):15-18.
  • Kane JM, Eerdekens M, Lindenmayer JP, Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
  • Fleischhacker WW, Eerdekens M, Karcher K, Treatment of schizophrenia with long-acting injectable risperidone: a 12-month, open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
  • Simpson GM, Mahmoud RA, Lasser RA, A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2003;67:1194-203.
  • Locklear J, Lasser R, Zhu Y, Hospitalization during long-term treatment with long acting risperidone. Poster presented at: 2004 Institute on Psychiatric Services’ Scientific Program, October 6-10, 2004, Atlanta, GA.
  • Llorca P-M, Devos E, Eerdekens M, Re-hospitalization rates with long-acting risperidone are lower than those reported for other antipsychotics. Poster presented at: the XXII Biennial Meeting of the Collegium Internationale Neuro-Psychopharmacologium, June 23-27, 2002, Montreal, Canada.
  • Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005;23(Suppl 1):3-16.
  • Edwards NC, Locklear JC, Rupnow MF, Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(Suppl 1):75-89.
  • Chue PS, Heeg B, Buskens E, Modeling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23(Suppl 1):62-74.
  • Weiden PJ, Kozma C, Groqq A, Partial compliance and risk rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91.
  • ABILIFY (aripiprazole) [package insert]. Princeton, NJ: Bristol-Myers Squibb, Rockville, MD: Otsuka America Pharmaceutical, Inc., 2007.
  • ZYPREXA (olanzapine) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2007.
  • SEROQUEL (quetiapine) [package insert]. Wilmington, DE: AstraZeneca, 2007.
  • RISPERIDAL (risperidone) [package insert]. Titusville, NJ: Janssen, LP, 2007.
  • GEODON (ziprasidone) [package insert]. New York, NY: Pfizer, Inc., 2007.
  • Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev 2003;4:CD004161.
  • Taylor DM, Young CL, Mace S, Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004;65:1076-83.
  • Muirhead D, Harvey C, Ingram G. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aust N Z J Psychiatry 2006;40:595-605.
  • Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30: 437-52.
  • Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003;64(Suppl 16):34-40.
  • Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-15.
  • Olivares JM, Rodriguez-Martinez A, et al; e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53.
  • Olivares JM, Peuskens J, Pecenak J, Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009; Jul 15 [Epub ahead of print].
  • Olivares JM, Rodriguez-Morales A, Diels J, Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96.
  • Gefvert O, Eriksson B, Persson P, Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005;8:27-36.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.